Concepedia

Publication | Open Access

Management of Paediatric Ulcerative Colitis, Part 1

461

Citations

401

References

2018

Year

TLDR

Ambulatory ulcerative colitis in children remains challenging, with about 20 % requiring colectomy during childhood. The aim was to standardize daily treatment of pediatric UC and IBD‑unclassified through detailed recommendations and practice points. The guidelines were developed via an extensive literature review, evidence appraisal, and expert consensus, producing 40 recommendations, 86 practice points, and decision‑making algorithms based on the Paediatric UC Activity Index. Consensus among 43 experts yielded 40 recommendations and 86 practice points with at least 88 % agreement, providing clinicians with a modern, safety‑aware management framework.

Abstract

The contemporary management of ambulatory ulcerative colitis (UC) continues to be challenging with ∼20% of children needing a colectomy within childhood years. We thus aimed to standardize daily treatment of pediatric UC and inflammatory bowel diseases (IBD)-unclassified through detailed recommendations and practice points.These guidelines are a joint effort of the European Crohn's and Colitis Organization (ECCO) and the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). An extensive literature search with subsequent evidence appraisal using robust methodology was performed before 2 face-to-face meetings. All 40 included recommendations and 86 practice points were endorsed by 43 experts in Paediatric IBD with at least an 88% consensus rate.These guidelines discuss how to optimize the use of mesalamine (including topical), systemic and locally active steroids, thiopurines and, for more severe disease, biologics. The use of other emerging therapies and the role of surgery are also covered. Algorithms are provided to aid therapeutic decision-making based on clinical assessment and the Paediatric UC Activity Index (PUCAI). Advice on contemporary therapeutic targets incorporating the use of calprotectin and the role of therapeutic drug monitoring are presented, as well as other management considerations around pouchitis, extraintestinal manifestations, nutrition, growth, psychology, and transition. A brief section on disease classification using the PIBD-classes criteria and IBD-unclassified is also part of these guidelines.These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.

References

YearCitations

Page 1